Latigo Biotherapeutics Q2 2026 Earnings Results & Report

Latigo Biotherapeutics EPS Results

• Actual EPS: -$27.59
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Latigo Biotherapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Latigo Biotherapeutics (NASDAQ:LTGO) is a clinical-stage biopharmaceutical company focused on developing non-opioid treatments for acute and chronic pain. The company’s research centers on selectively targeting Nav1.8, a sodium channel involved in the transmission of pain signals, with the goal of creating therapies that may provide pain relief without the risks associated with opioid medicines.

Latigo’s pipeline includes small-molecule Nav1.8 inhibitors, including LTG-001, an investigational candidate being evaluated for pain-related conditions. The company has studied its programs in clinical settings involving acute pain and neuropathic pain, including pain associated with diabetic peripheral neuropathy. Its development strategy is aimed at addressing a range of pain conditions for which existing treatments may be inadequate or carry significant safety concerns.

Latigo Biotherapeutics is based in the United States and advances its programs through preclinical research and clinical trials. The company became publicly traded on the Nasdaq under the symbol LTGO after completing its initial public offering in 2024. Additional information about the company’s leadership and commercial operations is limited, as Latigo remains focused primarily on research and development.